Dova Pharmaceuticals, Inc.
200 Garrett Street
About Dova Pharmaceuticals, Inc.Dova is a clinical-stage pharmaceutical company developing treatments for patients suffering from orphan diseases. The company’s lead compound candidate, AVA, recently completed two pivotal Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease undergoing an elective procedure.
September 23, 2016
CEO: Alex Sapir
Board Member: Paul B. Manning
Board Member: Sean Stalfort
15 articles with Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 15, 2018
To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 7796295 five to 10 minutes before the start of the call.
Mark will officially commence in his role as Chief Financial Officer of Dova on January 31st, 2018.
The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is May 21, 2018.
Dova reported a net loss of $9.7 million for the third quarter of 2017, compared to a net loss of $7.2 million for the same period in 2016.
A question-and-answer session will follow Dova's remarks.
Dova Pharma To Present Phase III Avatrombopag Data At The 2017 Liver Meeting Of The American Association For The Study Of Liver Diseases (AASLD)
Dova Pharma Announces New Drug Application Submission To FDA For Avatrombopag, A Second Generation Thrombopoietin Receptor Agonist
Dova Pharma Announces Hiring Of CEO And Presentation At The 35th Annual J.P. Morgan Healthcare Conference